Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

Zimmermann, Maria; Sanderson, Nicholas S R; Rasenack, Maria; Lalive d'Epinay, Patrice; Lang, Alois B; Curtin, François; Lindberg, Raija L P; Kappos, Ludwig; Derfuss, Tobias

doi:10.1212/NXI.0000000000000144

Scientific article

English

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

ContributorsZimmermann, Maria; Sanderson, Nicholas S R; Rasenack, Maria; Lalive d'Epinay, Patrice; Lang, Alois B; Curtin, François; Lindberg, Raija L P; Kappos, Ludwig; Derfuss, Tobias

Published inNeurology® neuroimmunology & neuroinflammation, vol. 2, no. 5, e144

Publication date2015

Abstract

To monitor the systemic immune responses of patients with multiple sclerosis (MS) under treatment with GNbAC1, a monoclonal antibody against the envelope protein of the MS- associated retrovirus, during a phase 2a trial.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques

Research groups

Scléroses en plaques, neuroimmunologie, encéphalite autoimmune expérimentale (843)

Citation (ISO format)

ZIMMERMANN, Maria et al. Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS. In: Neurology® neuroimmunology & neuroinflammation, 2015, vol. 2, n° 5, p. e144. doi: 10.1212/NXI.0000000000000144

Article (Published version)

Identifiers

PID : unige:89955
DOI : 10.1212/NXI.0000000000000144
PMID : 26380353

Journal ISSN2332-7812

446views

0downloads

Creation30/11/2016 15:42:00

First validation30/11/2016 15:42:00

Update time15/03/2023 02:06:00

Status update15/03/2023 02:06:00

Last indexation31/10/2024 06:26:28

Archive ouverte UNIGE

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

To monitor the systemic immune responses of patients with multiple sclerosis (MS) under treatment with GNbAC1, a monoclonal antibody against the envelope protein of the MS- associated retrovirus, during a phase 2a trial.

Technical informations